+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
Healthy Volunteers
ID06684106

Study of Ursodeoxycholic Acid to Prevent Glucose Problems in Adults Taking Statins for High Cholesterol

Led by First Affiliated Hospital Xi'an Jiaotong University · Updated on 2026-06-30

128

Participants Needed

2

Research Sites

28 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether Ursodeoxycholic acid UDCA can prevent glucose intolerance in adults with hyperlipidemia who are taking statin medications. The study also aims to assess the safety of UDCA and examine if it reduces other adverse events in patients using oral statins. This is a randomized controlled clinical trial conducted by the First Affiliated Hospital Xian Jiaotong University. Participants will be randomly assigned to one of two groups one receiving UDCA 500 mg daily combined with Atorvastatin, and the other receiving a placebo combined with Atorvastatin. Treatment lasts for 6 months, with follow-up visits on day 40, day 110, and day 180. The trial uses a double-blind method to compare the effects of UDCA and placebo when taken alongside statins. During the study, participants will have their blood sugar control measured using HbA1c at 6 months, along with fasting blood glucose, islet concentration, blood lipid levels, and body composition analysis including fat and muscle mass. These assessments help researchers understand how UDCA might affect glucose tolerance and other metabolic factors. Safety and adherence will be monitored throughout the 6-month treatment period.

CONDITIONS

Brief Title

Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance

Research Team

Y

Yue Yu

Y

Yue Wu, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here